A positive control was also included, namely desferrioxamine (DFO; 100 μM), which is a well-known iron-binding ligand that is clinically used for the treatment of iron overload disease (77, 78) that upregulates NDRG1 (33, 74). This evidence concerns the gene NDRG1 and Rare hereditary hemochromatosis.